Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial

IMPORTANCE: Atopic dermatitis is associated with substantial patient and caregiver burden. Currently available treatments for atopic dermatitis are inadequate or contraindicated for some patients. Abrocitinib (PF-04965842) is an oral Janus kinase 1 selective inhibitor under investigation for the tre...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:JAMA Dermatol
Main Authors: Gooderham, Melinda J., Forman, Seth B., Bissonnette, Robert, Beebe, Jean S., Zhang, Weidong, Banfield, Chris, Zhu, Linda, Papacharalambous, Jocelyne, Vincent, Michael S., Peeva, Elena
Format: Artigo
Sprog:Inglês
Udgivet: American Medical Association 2019
Fag:
Original Investigation
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6777226/
https://ncbi.nlm.nih.gov/pubmed/31577341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2019.2855
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker